Form 4: Celldex Therapeutics Director Herbert Conrad Granted Stock Options

Celldex Therapeutics Director Herbert J. Conrad was granted 16,500 non-qualified stock options with an exercise price of $19.53, exercisable from June 5, 2026, and expiring on June 5, 2035.

Summary

• Herbert J. Conrad, a Director of Celldex Therapeutics, Inc. (CLDX), was granted non-qualified stock options.
• The grant occurred on June 5, 2025.
• The options are for 16,500 shares of common stock.
• The exercise price for these options is $19.53 per share.
• The options become exercisable on June 5, 2026, and expire on June 5, 2035.
• This grant was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive signal of continued alignment between management and shareholder interests, and it is a routine part of executive compensation.

Positives

• The grant of non-qualified stock options to Director Herbert J. Conrad aligns his interests with those of shareholders, incentivizing long-term performance.
• The options were granted under the company's 2021 Omnibus Equity Incentive Plan, indicating a structured approach to executive compensation and retention.

Negatives

• No specific negative financial or operational information is disclosed in this Form 4 filing, as it primarily reports an insider transaction.

Risks

• This Form 4 filing does not disclose specific risks related to the company's operations or financial health, as its purpose is to report an insider transaction.

Future Outlook

This Form 4 filing does not provide forward-looking statements or guidance regarding the company's future performance or strategic outlook, as its primary purpose is to report an insider transaction.

Management Comments

• This Form 4 filing does not contain direct quotes or paraphrased statements from company management, as it is a regulatory disclosure of an insider transaction.

Industry Context

This Form 4 filing, reporting an insider's stock option grant, is a routine regulatory disclosure and does not provide specific insights into broader industry trends or competitive landscape. However, equity grants are a common practice across the biotechnology and pharmaceutical sectors to attract and retain key talent.

Comparison to Industry Standards

• This Form 4 filing, detailing a stock option grant to a director, does not provide sufficient information for a direct comparison to specific global benchmarks, comparable companies, or project results. The grant of stock options is a standard component of executive and director compensation packages across various industries, including biotechnology, aiming to align interests with shareholders.

Related Party Transactions

• The grant of non-qualified stock options to Herbert J. Conrad, a Director of Celldex Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's interests with shareholders, potentially incentivizing long-term value creation. However, future exercise of options could lead to minor dilution.
• Employees: While not directly impacting all employees, such grants are part of a broader compensation strategy that can affect morale and retention of key personnel.

Next Steps

• This Form 4 filing does not outline specific future actions, events, or milestones for the company, as it is a report of a completed insider transaction.

Key Dates

Keywords

Celldex Therapeutics, CLDX, Form 4, Stock Options, Insider Transaction, Herbert J. Conrad, Equity Incentive Plan, Director Compensation